Business Wire

CA-SYNACK

6.6.2019 17:02:17 CEST | Business Wire | Press release

Share
Crowdsourced Security Testing that Puts Privacy First

Today, Synack, the most trusted crowdsourced security testing platform and top choice of major enterprises and governments, becomes the only crowdsourced penetration testing company to offer secure and managed workspaces with endpoint control. LaunchPoint+ extends Synack’s original LaunchPoint VPN offering by providing a managed workspace environment for crowdsourced testing of enterprise and government assets.

In the midst of calls for greater consumer privacy from the European Commission to Apple, and states like NY and CA introducing bold privacy bills, Synack is launching their new LaunchPoint+ product to help organizations meet today’s rising security standards. Just as Apple now provides privacy-as-a-service (PaaS) to accommodate consumer privacy demands in their latest iOS upgrade, Synack is providing additional privacy and data control to its customers.

As GDPR, HIPAA, PCI-DSS and ISO 27001 require increasingly stringent requirements for data privacy, Synack has developed a new offering to help meet, and in some cases exceed, what is required. In use cases that require extra care (such as where PII data is involved), consumers and regulators alike are increasingly demanding more attention for data privacy. A violation of GDPR could result in a fine of up to 4% of annual revenue, incentivizing organizations to protect the data in their care.

Many organizations, both governments and enterprises, are held to regulatory standards that demand heightened requirements around privacy. For others such as Apple, enforcement of privacy is a way to develop more trust with their customers and differentiate their brands. In a recent survey by SAS, 73% of consumers said their concerns over data privacy were increasing. Synack has responded by providing managed workspaces with endpoint controls to give these organizations the data protection and privacy environment during the testing period that they need.

As the leader of crowdsourced security, Synack has continuously brought to market new technology features that build, measure, and demonstrate trust between enterprises and their customers, and organizations and ethical hackers. Through innovations like the Attacker Resistance Score, Coverage Analytics, Trust Report, and Guardians of Trust Awards, Synack has put the trust and privacy of its customers first. LaunchPoint+ is another example of that commitment.

For Synack customers, the company’s new workspace will enable endpoint control, data privacy objectives, and improved trust between customers and researchers.

“We’ve set out to build trust between organizations and ethical hackers since our founding in 2013. We’re really excited to continue enhancing the Synack platform with technology feature updates like LaunchPoint+, because these are what give customers more control and make the crowdsourced testing model more trusted,” Synack CTO and co-founder Mark Kuhr said.

“The ability to have enhanced security controls directly applied to the attack workstation will help ensure data privacy and compliance requirements are met and consistently enforced,” says David Charlton, former Head of Penetration Testing at J.P. Morgan Chase & Co, and Synack’s Head of Product Strategy.

For Synack Red Team researchers, LaunchPoint+ will eradicate the need to manually connect to a VPN server and ensure a stable connection with reduced network latency. When asked for feedback, Synack Red Team researchers said they were “happy with the concept”, “a fan of the increased bandwidth”, and could “definitely see myself using this a lot.”

As more security teams move towards crowdsourced penetration testing, Synack leads the way in trust by offering features like LaunchPoint+ that ensure private, safe and controlled testing.

About Synack

Synack, the most trusted crowdsourced security company, delivers comprehensive and continuous penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create a scalable, effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .

Contact:

Ellie McCardwell press@synack.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 08:00:00 CEST | Press release

A hybrid quantum-classical algorithm, executed end to end on IQM hardware, produced feasible schedules with Deutsche Bahn, the German rail operator, using a real operational dataset of 190 trips across five German cities. The approach runs on today’s hardware and is designed to improve automatically as quantum processors scale, offering enterprises a model for extracting value now, ahead of fault-tolerant computing. The collaboration reflects IQM’s push into enterprise adoption. The company has sold 24 quantum computers worldwide and listed on the Nasdaq Global Select Market and Nasdaq Helsinki in July 2026 under the ticker IQMX. IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.busines

Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 07:00:00 CEST | Press release

Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent la

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca

STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release

STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo

Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release

A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye